Table 4.
Study | Methods | Sample | Treatment strategy | Recanalisation | sICH | mRS 0–2 at 90 days | Mortality at 90 days |
---|---|---|---|---|---|---|---|
Rangel-Castilla et al.12 | Retrospective single-centre | 45 | Anterograde/retrograde | 87% TICI ≥ 2b | 4.4% | 73.3% | 11%a |
Lockau et al.13 | Retrospective single-centre | 37 | Anterograde/retrograde | 73% TICI ≥ 2b | 10.8%b | 45.9% | 18.9% |
Lescher et al.20 | Retrospective single-centre | 39 | Anterograde/retrograde | 64% TICI ≥ 2b | 10% | 36% | 10% |
Heck and Brown21 | Retrospective single-centre | 23 | Anterograde | 91% TICI ≥ 2b | 22% | 52% | 39% |
Stampf et al.22 | Retrospective single-centre | 24 | Anterograde/retrograde | 62.5% TICI ≥ 2b | 16.6% | 29.2% | 16.6% |
Cohen et al.23 | Retrospective single-centre | 24 | Anterograde | 79% TIMI 3, TICI ≥ 2b | 0 | 76% | 8% |
Maurer et al.24 | Retrospective single-centre | 43 | Anterograde | 76.7% TICI ≥ 2b | 11.6%b | 32.6% | 32.6%c |
Our study | Retrospective multi-centre | 60 | Anterograde/retrograde | 78.3% mTICI ≥ 2b | 11.7% | 50% | 20% |
Mortality in hospital.
Symptomatic parenchymal haemorrhage.
Mortality at discharge.
TIMI: thrombolysis in myocardial infarction; TICI: thrombolysis in cerebral ischaemia.